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Abstract
Introduction: Daily interruption of sedation (IS) has been implemented in 30 to 40% of intensive care units
worldwide and may improve outcome in medical intensive care patients. Little is known about the benefit of IS in
acutely brain-injured patients.
Methods: This prospective observational study was performed in a neuroscience intensive care unit in a tertiary-
care academic center. Twenty consecutive severely brain-injured patients with multimodal neuromonitoring were
analyzed for levels of brain lactate, pyruvate and glucose, intracranial pressure (ICP), cerebral perfusion pressure
(CPP) and brain tissue oxygen tension (PbtO2) during IS trials.
Results: Of the 82 trial days, 54 IS-trials were performed as interruption of sedation and analgesics were not
considered safe on 28 days (34%). An increase in the FOUR Score (Full Outline of UnResponsiveness score) was
observed in 50% of IS-trials by a median of three (two to four) points. Detection of a new neurologic deficit
occurred in one trial (2%), and in one-third of IS-trials the trial had to be stopped due to an ICP-crisis (> 20
mmHg), agitation or systemic desaturation. In IS-trials that had to be aborted, a significant increase in ICP and
decrease in PbtO2 (P < 0.05), including 67% with critical values of PbtO2 < 20 mmHg, a tendency to brain metabolic
distress (P < 0.07) was observed.
Conclusions: Interruption of sedation revealed new relevant clinical information in only one trial and a large
number of trials could not be performed or had to be stopped due to safety issues. Weighing pros and cons of
IS-trials in patients with acute brain injury seems important as related side effects may overcome the clinical
benefit.
Introduction
Titrating sedatives and analgesics to achieve the right bal-
ance between deep sedation and wakefulness and to ame-
liorate patients’ comfort in the intensive care unit (ICU) is
an integral part of critical care [1]. Over-sedation can lead
to prolonged duration of mechanical ventilation and ICU
stay and increase the incidence of secondary complica-
tions, including nosocomial infections and delirium.
Daily interruption of sedation trials (IS-trials) have been
implemented in many surgical and medical ICUs after ran-
domized controlled trials demonstrated that IS decreased
the duration of mechanical ventilation, shortened the hos-
pital stay and may, in combination with spontaneous
breathing trials, improve outcome in medical intensive
care patients [2-6]. Another important issue of IS-trials is
that the amount of sedatives and analgesics could also be
reduced [2,3]; however, the result of a recent meta-analysis
of five randomized controlled trials comparing IS with no
interruption in 699 critically ill patients challenges pre-
vious findings as a reduction in duration of mechanical
* Correspondence: raimund.helbok@uki.at; nbadjatia@umm.edu
1Division of Neurocritical Care, Department of Neurology/Neurolsurgery,
Columbia University Medical Center, Milstein Hospital 8-300 Center, 177 Fort
Washington Ave., New York, NY 10032, USA
Full list of author information is available at the end of the article
Helbok et al. Critical Care 2012, 16:R226
http://ccforum.com/content/16/6/R226
© 2012 Helbok et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
ventilation, length of ICU stay or mortality could not be
confirmed [7].
IS-trials in patients with acute brain injury are not well
studied and the only case series, including 12 patients with
traumatic brain injury (TBI) and 9 subarachnoid hemor-
rhage (SAH) patients, showed that the risk of elevated
intracranial pressure (ICP) and low cerebral perfusion
pressure (CPP) is evident during these trials [8,9]. Cerebral
hypoperfusion and raised ICP may result in an imbalance
of energy supply and demand especially for the injured
brain and, therefore, aggravate the risk for metabolic dis-
tress and brain tissue hypoxia [10-16]. These potential
side-effects of IS-trials have not been investigated so far
and may limit their clinical benefit in severely brain
injured patients. We hypothesized that IS-trials may be
harmful for these patients and examined the effects of IS-
trials on brain hemodynamic changes, brain tissue oxygen
tension and metabolism using multimodal neuromonitor-
ing devices in patients with acute brain injury.
Materials and methods
Patients
Between March 2009 and June 2010, 20 consecutive
patients with acute brain injury were admitted to the neu-
rological-ICU (NICU) at Columbia University Medical
Center and underwent brain multimodality monitoring
according to our institutional protocol. At the time moni-
toring was started, all patients had a Glasgow Coma Scale
≤ 8. In this prospective observational study, we investi-
gated the effect of interruption of sedatives and analgesics
on hemodynamic and brain metabolic changes. All inter-
ruption in sedation trials were conducted as part of the
standard of care in the Neuro-ICU; therefore, consent was
not necessary. Data were collected as part of an ongoing
prospective database approved by the Institutional Review
Board at Columbia University, New York.
Intracranial monitoring
Multimodality monitoring included at least ICP, cerebral
microdialysis, and brain tissue oxygen tension (PbtO2)
measurement and was initiated if (1) it was unlikely that
the patient gains consciousness within the following
48 hours, and (2) the patient had a high probability to sur-
vive for the next 48 hours. Technical details on probe
location, and practical aspects of neuromonitoring have
been previously reported and are briefly summarized here
[10,11,17]. A CMA-70 microdialysis catheter (CMA/
MicrodialysisTM, Stockholm, Sweden), a flexible polaro-
graphic Licox Clark-type probe (Licox GMBHTM, Kiel,
Germany; Integra-NeurosciencesTM) and a parenchymal
ICP monitoring device (Integra-NeurosciencesTM, Plains-
borough, NJ, USA) were inserted at the bedside, fixed with
a triple-lumen bolt via a frontal approach into the hemi-
sphere deemed at greatest risk for secondary injury (that
is, perihematomal or pericontusional tissue, or the ipsilat-
eral anterior watershed zone in lateralized SAH), or in the
right frontal lobe in patients with diffuse injury. The loca-
tion in the white matter was confirmed by brain CT scan
immediately after the procedure. Brain metabolic para-
meters included glucose, pyruvate and lactate concentra-
tions and were analyzed hourly (CMA-600; CMA/
MicrodialysisTM).
Clinical management
Patient care for subarachnoid and intracerebral hemor-
rhage and TBI conformed to guidelines established by the
American Heart Association and the Brain Trauma Foun-
dation [18-20]. In general, hemodynamic and fluid man-
agement was targeted to maintain CPP ≥ 60 mmHg, and
ICP < 20 mmHg. Adequate sedation and analgesia was
performed with a combination of dexmedetomidine, mida-
zolame, propofol and fentanyl. Fever was aggressively trea-
ted using intravascular (Celsius-Control-SystemTM,
Innercool Therapies, Inc., San Diego, CA, USA) or surface
cooling (Arctic-Sun Cooling-SystemTM, Medivance Inc.,
Louisville, CO, USA) devices. None of the patients were
cooled during the IS-trial. Shivering was assessed using
the Bedside Shivering Assessment Scale (BSAS) and
graded from 0 to 3 points (0 = no shivering noted on pal-
pation of the masseter, neck or chest wall; 1 = shivering
localized to the neck and/or thorax only; 2 = shivering
involves gross movement of the upper extremities (in
addition to neck and thorax) and; 3 = shivering involves
gross movements of the trunk and upper and lower extre-
mities) [21]. Treatment of shivering included acetamino-
phen, buspirone and skin counter warming with forced air
at 43°C and magnesium, meperidine and/or dexmedetomi-
dine were used when primary measures failed [21,22].
Procedure
The goal of the sedation-analgesic regimen in the Neuro-
ICU is to utilize the minimal amount of drugs necessary
to adequately maintain a safe environment for ventilation,
cerebral and systemic hemodynamics while also maximiz-
ing the ability to track changes in the neurological exami-
nation. Every patient was assessed daily by the treating
neurointensivists (JC, SM, KL, NB) for IS-trial eligibility.
Interruption was not attempted if one of the following
conditions was present: severe hemodynamic instability,
ICP > 18 mmHg and the use of sedatives as a primary
treatment for ongoing elevated ICP. Other safety concerns
included sedative infusions for active seizures, escalating
sedative doses due to ongoing agitation or respiratory dis-
tress, and evidence of active myocardial ischemia within
the last 24 hours. Patients who were eligible underwent
interruption of all sedatives and analgesics.
Patients passed the IS-trial if they tolerated sedative
interruption for at least 30 minutes (maximum 60 minutes)
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until awake without exhibiting failure criteria. Patients
were monitored by the intensive-care staff or study person-
nel during the whole trial time. No change was made in
fraction of inspired oxygen (FIO2) or positive end-expira-
tory pressure (PEEP) during the trial. Trained study per-
sonnel did neurological assessments, including the
Glascow Coma Score (GCS) and FOUR Score, at baseline
and after the 60-minute trial or before sedatives and
analgesics had to be restarted [23].
Patients failed the IS-trial if they developed sustained
anxiety, agitation or pain defined by clinical and cardio-
pulmonary stress and/or a respiratory rate of more than
35 breaths-per-minute (bpm) for > 5 minutes, an SpO2
< 88% for > 5 minutes, ICP > 20 mmHg and/or CPP <
50 mmHg for > 5 minutes, an acute cardiac dysrhyth-
mia, or ≥ 2 signs of respiratory distress, including tachy-
cardia (> 130 bpm), bradycardia (< 50 bpm), use of
accessory muscles, abdominal paradox, diaphoresis or
marked dyspnoea. When patients failed an IS-trial, seda-
tives and analgesics were restarted at half the previous
dose and titrated to the desired level of sedation. Micro-
dialysis probes were analyzed, per protocol, before medica-
tion was stopped, and in a 60-minute interval thereafter by
the ICU staff nurse.
Data acquisition
The Solar-8000i system utilizing the General Electric Med-
ical Systems Information Technologies’ Unity Network®
(Milwaukee, WI 53223, USA) was used to capture physio-
logical data. A high resolution data acquisition system
(BedmasterEX, Excel Medical Electronics, Jupiter, FL,
USA) using the open architecture of the Unity Network®
automatically acquired vital sign, alarm and waveform
data from all the patient monitoring devices in the NICU.
Digital data were acquired every five seconds and recorded
in a SQL-database. Waveform data were stored at a reso-
lution of 240 Hz in binary files. The LICOX and brain
metabolism data were incorporated into the data acquisi-
tion system utilizing the communications (COM) port on
the device and is plugged into a serial-to-TCP/IP interface
device (Equinox ESP-8, Avocent, Sunrise, FL, USA).
Physiological variables including heart rate (HR), arterial
blood pressure, respiratory rate (RR), and oxygen satura-
tion (SpO2) were continuously monitored in all patients.
Statistical analysis
Statistical analysis of pooled data was performed using
Mann-Whitney-U, Student-t-Test for continuous variables
and chi-square test for categorical variables as appropriate.
RR, HR, mean arterial pressure (MAP), CPP and PbtO2
measurements were averaged every 15 minutes and time-
locked to the IS-trial. Data are expressed as mean (± SD)
or median (IQR) unless otherwise indicated. Time series
data were analyzed using a multivariable general linear
model (GLM). The model was extended by generalized
estimating equations (GEE) using an autoregressor of the
first order (AR-1) for model estimation of the data correla-
tion structure of repeated observations within-subjects.
Least significant difference (LSD) post-hoc comparisons of
the estimated marginal means were used to assess differ-
ences in outcome variables over time. All statistical ana-
lyses were performed using SPSS 19 software (SPSS Inc.,
Chicago, IL, USA). Differences were considered significant
at P < 0.05.
Results
Baseline characteristics are shown in Table 1. Neuromoni-
toring was initiated at Day 2 after ictus (IQR, 1 to 4) and
maintained for 9 days (IQR, 6 to 13). IS trials were per-
formed in all patients, however, not on weekends (n = 40),
at the day of neuromonitoring probes insertion (n = 20),
due to technical problems (n = 14) and when patients
were off sedation (n = 19) leaving 82 of 175 days eligible
for awakening trials (47%). Interruption of sedation and
analgesics was not attempted on 28 days (34%) due to
Table 1 Baseline characteristics (N = 20)
Demographics and past medical history
Age, y 47 (34 to 56)






Admission GCS 8 (5 to 14)
Admission Hunt-Hess grade 5 (4 to 5)





APACHE physiologic score 15 (6 to 23)
Systolic blood pressure, mmHg 134 (116 to 160)
Neuromonitoring
Days to Monitoring 2 (1 to 4)
Days with Monitoring 9 (6 to 13)
Outcome
ICU LOS 18 (10 to 26)
Hospital LOS 27 (18 to 37)
Discharge modified Rankin Scale 5 (4 to 5)
< = 3 3 (15)
4 3 (15)
5 9 (45)
Hospital mortality 5 (25)
Values are presented as mean (SD), median (IQR) or number (%). ICH,
intracerebral hemorrhage; SAH, subarachnoid hemorrhage; TBI, traumatic
brain injury
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hemodynamic instability (on 7 days), critical ICP values at
baseline (on 12 days), and the need for sedatives (on 9
days), resulting in a total of 54 IS-trials being performed.
Intervention and neurological assessment
Thirty-six IS-trials (67%) were fully completed and one-
third of all trials (n = 18, 33%; 12/20 patients) had to be
aborted due to ICP crisis (n = 9, 50%), agitation (n = 4,
22%), systemic desaturation (n = 2, 11%) or a combination
of all (n = 3, 17%). Trial failure was not associated with a
specific disease entity or a specific time period after brain
injury. Detection of a new neurologic deficit occurred in
one trial (2%). In this patient an increase in brain lactate
and slight decrease in brain glucose (to 1 mmol/L) was
noted hours before the IS-trial was performed. At the trial
start, patients received a median of two drugs (IQR, 2 to -3)
including a combination of dexmedetomidine (n = 45,
median = 1 μg/kg/h, 0.7 to 1.0 μg/kg/h), midazolam (n = 8,
median dose = 1 mg/kg/h, 1 to 7 mg/kg/h), propofol (n =
43, median dose = 30 μg/kg/h, 25 to 40 μg/kg/h), and fenta-
nyl (n = 30, median = 28 μg/h, 25 to 50 μg/h). The median
time off sedation, including all trials, was 35 minutes (30 to
40 minutes). An increase in the FOUR Score (Full Outline
of UnResponsiveness score) was observed in 50% of IS-
trials by three (two to four) points (P < 0.05) (Figure 1A).
IS-trial and hemodynamic changes
Average values of HR, RR, MAP and CPP at baseline, dur-
ing the trial and two hours after restart of sedation are
shown in Figure 1B-E. All parameters significantly
increased from baseline (P < 0.001) without discriminating
completed trials from interventions where sedation had to
be restarted early (P > 0.6). Heart rate increased from 73 ±
4 bpm to a maximum of 97 ± 6 bpm, respiratory rate
from 18 ± 2 to 30 ± 3/minute, MAP from 103 ± 5 to
117 ± 6 mmHg, and CPP 93 ± 5 to 111 ± 6 mmHg (P <
0.001, respectively). ICP was below 15 mmHg in all
patients at baseline and remained stable in patients where
the trial was completed. In patients where the trial had to
be stopped early, ICP increased from a baseline of 12 ± 2
to 22 ± 6 mmHg (P < 0.05) (Figure 1F). No further
increase in ICP was observed when sedation was restarted.
IS-trial and changes in brain tissue oxygen tension and
cerebral metabolism
Brain microdialysate was sufficiently analyzed during 43
IS-trials (78%). Brain tissue lactate, pyruvate, lactate-
pyruvate ratio (LPR) and glucose concentration did not
change from baseline in both groups (Figure 2A, B). LPR
increased by 5% (IQR, 3 to 14%) in 20 trials and decreased
by 5% (IQR, 1 to 8%) in 23 trials. We found a tendency to
Figure 1 Clinical and hemodynamic changes during is-trials. Panel A shows median increase of GCS (empty circle) and the Four score (filled
circle) during the IS-trial. Panel B-F gives average time course of cardiopulmonary, cerebrovascular parameters and ICP (y-axis) at baseline (time =
0) during the trial (grey square) and over 2 hours following restart of sedation and analgesics (x-axis) in patients where the trial was completed
(empty square) and aborted (filled square). P-value is given for significant differences of time points (Panel A) or differences of parameters over
time (Panel B-F) (** = P < 0.001, * = P < 0.05). On Panel B-F error bars represent means and one standard error of n = 54 individual trials. CPP,
cerebral perfusion pressure; HR, heart rate; ICP, intracranial pressure; MAP, mean arterial pressure; RR, respiratory rate.
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higher overall LPR (P = 0.07) and lower overall brain glu-
cose (P = 0.06) in patients who failed the trial.
Brain tissue oxygen tension was 28 ± 2 mmHg at base-
line and significantly decreased to 19 ± 2 mmHg in
patients who developed one of the trial failure criteria (P <
0.05) (Figure 2C). In all of these trials a reduction of PbtO2
compared to baseline was observed, and in 67% brain tis-
sue hypoxia (PbtO2 < 20 mmHg) occurred (Figure 2D).
PbtO2 did not decrease below 15 mmHg in any patient. In
patients who completed the IS-trial, a slight increase in
PbtO2 (P = 0.07) was observed. In these trials PbtO2 was
positively correlated with CPP (r = 0.54, P < 0.01).
Shivering (BSAS > 0) was observed in half of the trials
and more commonly occurred in patients who failed the
IS-trial (77% versus 43%, P < 0.05) (Figure 2E) [21].
Discussion
In the present study we evaluated the effect of interruption
of sedatives and analgesics on neurologic assessment,
hemodynamic changes, brain metabolism and brain tissue
oxygen tension in acutely brain injured patients. Our main
findings were that IS-trials were not attempted on one-
third of eligible days due to safety concerns, and that one-
third of performed trials had to be stopped due to a
critical increase in ICP and impending brain tissue
hypoxia. All IS-trials were associated with cardiopulmon-
ary stress, and detection of a new neurological deficit that
led to a change in management occurred in only one trial
(2%).
It is important to weigh pros and cons of IS-trials in
patients with acute brain injury. Spontaneous awakening
trials have been considered safe in medical and surgical
ICU patients, but have not been validated for NICU
patients [2-6]. In a recent meta-analysis, including 699
critically ill patients, daily sedation interruption was not
associated with a reduction in duration of mechanical
ventilation, length of ICU stay or mortality, and the
authors call for more evidence before IS-trials should be
recommended [7]. This may especially hold true for
acutely brain injured patients, where an imbalance of
energy supply and demand is common and additional
stress may result in cerebral metabolic distress and brain
tissue hypoxia [10-16]. We observed a sympathetic stress
response with increased heart rate, respiratory rate and
MAP during all IS-trials, which is in line with a recent
report showing an excess of endogenous catecholamines
and corticoids during neurologic wake-up tests [24].
Of interest is the observed effect of IS-trials on cerebral
Figure 2 Changes in brain metabolism, brain tissue oxygen tension and bsas during is-trials. Average time course of MD parameters
before and after the IS-trial (Panel A-B). Panel C shows average time course of PbtO2 at baseline (time = 0) during the trial (grey-square) and
over two hours following restart of sedation and analgesics (x-axis). Panel D gives the percentage of trials with PbtO2 < 20 mmHg in both
groups. In Panel E the bedside shivering scale of both groups is shown. Groups are reflected as patients who completed the trial (empty square)
and patients who developed a failure criteria (filled square). Error bars represent means and one standard error of n = 54 individual trials. P-value
is given for significant differences (** = P < 0.001, * = P < 0.05). BSAS, bedside shivering assessment scale; LPR, lactate-pyruvate ratio; PbtO2, brain
tissue oxygen tension.
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oxygen balance. PbtO2 increased in patients where the IS-
trial could be completed with a positive correlation of
PbtO2 and CPP, which may be explained by increased
oxygen delivery without excessive energy consumption
[25]. In patients who failed the trial, we observed a
decrease in PbtO2 to critical values (< 20 mmHg) in 67%
of IS-trials. In parallel, elevation in ICP was observed,
which may increase the demand of oxygen and, therefore,
decrease brain tissue oxygen tension. Normalization of
PbtO2 after ICP decreased to normal values supports this
hypothesis. Increased systemic oxygen utilization may
also result in low brain PbtO2 levels, which is supported
by the observation of systemic desaturation in 5 of 18
trials that had to be aborted and the notification of shi-
vering during IS-trials, as noted by the BSAS-score [21].
The BSAS-score increased by two points, reflecting shi-
vering with involvement of the neck, thorax and gross
movement of the upper extremities [21], which was com-
mon in patients who failed the IS-trial. Shivering can
trigger massive increases in systemic resting energy
expenditure, and oxygen consumption [21,22], and can
potentially increase the risk of brain tissue hypoxia [16].
Therefore, shivering should be effectively treated by
pharmacological and non-pharmacological means [26].
A marked increase in ICP and critical decrease in CPP
has been previously described in TBI and SAH patients
during neurologic wake up trials [8]. Similarly, we found
that elevated ICP was the most often reported failure
criteria in our trials. Restarting sedation resulted in an
ICP decrease to normal values without the need for
additional osmotherapy.
Patients who failed the trial had a trend towards higher
LPR and lower brain glucose at trial start and during the
observation period. This reflects that these patients were
already more prone to brain metabolic distress at trial
start, which may be a valuable safety consideration of IS-
trials in critically ill neurologic patients. Anaerobic meta-
bolism and mitochondrial dysfunction is common after
severe head injury and associated with the initial trauma,
increased ICP, global cerebral edema after SAH, focal or
generalized brain edema, fever, seizures and others
[10-16]. Recently, derangement in neuronal signal proces-
sing and energy metabolism potentially leading to sus-
tained neuronal depolarization and depression of brain
electrical activity have been described after SAH and TBI
[27,28]. In these conditions of deranged cerebral metabo-
lism, the human brain may be more vulnerable to systemic
and cerebral stress. It is important to mention that ICP
increases and PbtO2 decreases did not result in brain meta-
bolic changes in our patients, most likely due to the short
duration of these episodes as all of these parameters were
predefined as trial-failure criteria. Without online cerebral
hemodynamic and brain oxygenation values IS-trials may
result in prolonged episodes of elevated ICP or brain tissue
hypoxia which are associated with anaerobic brain meta-
bolism and poor outcome [11,12,29]. For further compara-
tive studies, monitoring ICP and PbtO2 during IS-trials
seems important, whereas microdialysis parameters seem
to discriminate at baseline without adding further infor-
mation during IS-trials.
One of the major rationales in the benefit of daily awa-
kening trials is the additional information gained from a
reliable clinical assessment. An increase in GCS and the
FOUR score was observed in half of our patients. Evidence
of a new focal neurologic deficit was found in only one
SAH patient with known cerebral vasospasm who devel-
oped motor weakness of the lower limb. Repeated intra-
arterial verapamil application resulted in increased perfu-
sion and prevented cerebral infarction.
With limited clinical benefit of IS-trials in NICU
patients, a sedation algorithm guided by commonly used
sedation scales may be sufficient. However, the problem
with this approach is that we still lack validated sedation
scales to guide the neurointensivist in the management of
acutely brain injured patients. At the end of each IS-trial,
sedatives and analgesics were restarted at half the previous
dose and titrated to the desired level of sedation. We
believe that this strategy is important to prevent over-
sedation of our NICU patients, which is a strong predictor
for delirium and prolonged ICU stay. We used a fairly
advanced sedation regimen, including dexmedetomidine,
on our patients which may not be standard in other
NICUs, which may have contributed to our findings and
also explain differences to positive trials on medical
patients [2-6].
Several potential weaknesses of this study deserve men-
tion. The sample size is small and the population hetero-
geneous; however, a subanalysis, including SAH patients
only, did not change our findings. Still, a potential selec-
tion bias limits generalizability of our data to all patients
with severe brain injury since only poor grade patients
that fulfill the inclusion criteria outlined in the methods
section underwent multimodal neuromonitoring (that is,
GCS < 8). One may argue that hemodynamic deterioration
during IS-trials should be expected in this selective patient
population; however, these are the patients with highest
risk for secondary brain damage (that is, delayed cerebral
ischemia (DCI)) where a proper clinical exam may
uncover deterioration early. In one-third of our trials, criti-
cal ICP elevation was observed even after a specialized
clinician considered the patient’s condition as safe.
Another point why our results should not be generalized
is that IS-trials were limited to the neuromonitoring time
and we may have missed important trial days. Neuromoni-
toring was started at Day 2 after ictus and the initial 48
hours may even be more critical for sedation interruption,
even resulting in a higher number of side effects and safety
concerns than described in this study. By increasing the
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sample size we would have been able to better describe a
hemodynamic and clinical profile of patients where IS-
trials are at high risk for being aborted. Another potential
bias in this study is the large number of days when IS-
trials were not attempted due to weekend days, or where
the intervention was not considered safe. We do not know
how these patients would have performed; however, based
on our results, it is very likely that patients who were
excluded from the trial due to hemodynamic or cerebral
hemodynamic abnormalities would have deteriorated
further during the trial. Another limitation is that we did
not measure cerebral blood flow (CBF) and the status of
cerebral autoregulation in all patients, however, observed
an increase in respiratory rate in all patients. Hyperventila-
tion is associated with cerebral vasoconstriction and
decreased CBF and limited energy supply to the brain
(oxygen and glucose delivery).
Conclusions
Interruption of sedation revealed new relevant clinical
information in only one trial. A large number of trials
could not be performed or had to be stopped due to safety
issues. Although serious brain metabolic changes were not
observed, related side effects may overcome clinical benefit
in severely brain injured patients and the information
gained by multimodal neuromonitoring can be used to
safely conduct IS-trials in certain patients and disease
states. Contrarily, long-term benefits of IS-trials in selected
patients with severe brain injury may still prove beneficial.
Future studies should evaluate the ability of advanced neu-
romonitoring techniques to determine patients most suita-
ble for daily sedation interruption.
Key messages
• Daily interruption of sedation (IS-trials) is consid-
ered safe in medical intensive care patients and asso-
ciated with improved outcome.
• Little is known about the benefit of IS-trials in
acutely brain-injured patients.
• IS-trials were associated with cardiopulmonary dis-
tress and brain tissue hypoxia and ICP crisis (one-
third) in acutely brain injured patients.
• Weighing pros and cons of IS-trials in patients
with acute brain injury seems important.
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